Abstract:Objective: The expression of connective tissue growth factor mRNA in human kidneys may serve as an early marker for lupus nephritis progression. Therefore, we speculated that connective tissue growth factor may be involved in the pathogenesis of systemic lupus erythematosus and lupus nephritis. In this study, we set out to investigate the associations between serum connective tissue growth factor levels and clinicopathological features of patients with systemic lupus erythematosus and lupus nephritis. Methods: Serum samples from patients with non-renal systemic lupus erythematosus, renal biopsy-proven lupus nephritis and healthy control subjects were detected by enzyme-linked immunosorbent assay for serum connective tissue growth factor levels. The associations between connective tissue growth factor levels and clinicopathological features of the patients were further analysed. Results: The levels of serum connective tissue growth factor in patients with non-renal systemic lupus erythematosus and lupus nephritis were both significantly higher than those in the normal control group (34.14 ± 12.17 ng/ml vs. 22.8 ± 3.0 ng/ml, p<0.001; 44.1 ± 46.8 ng/ml vs. 22.8 ± 3.0 ng/ml, p = 0.035, respectively). There was no significant difference of the serum connective tissue growth factor levels between non-renal systemic lupus erythematosus and lupus nephritis group (34.14 ± 12.17 ng/ml vs. 44.1 ± 46.8 ng/ml, p = 0.183). Serum connective tissue growth factor levels were significantly higher in lupus nephritis patients with the following clinical manifestations, including anaemia (51.3 ± 51.4 ng/ml vs. 23.4 ± 9.7 ng/ml, p<0.001) and acute renal failure (85.5 ± 75.0 ng/ml vs. 31.2 ± 21.8 ng/ml, p = 0.002). Serum connective tissue growth factor levels in class IV were significantly higher than that in class II, III and V (57.6 ± 57.5 ng/ml vs. 18.7 ± 6.4 ng/ml, p = 0.019; 57.6 ± 57.5 ng/ml vs. 25.2 ± 14.9 ng/ml, p = 0.006; 57.6 ± 57.5 ng/ml vs. 30.5 ± 21.3 ng/ml, p = 0.017, respectively). Serum connective tissue growth factor levels were significantly higher in those with both active/chronic lesions than those in those with active lesions only in either class IV (84.9 ± 69.6 ng/ml vs. 40.0 ± 40.2 ng/ml, p = 0.001) or in combination of class III and IV lupus nephritis (63.3 ± 63.4 ng/ml vs. 38.3 ± 37.9 ng/ml, p = 0.035, respectively). Serum connective tissue growth factor levels were negatively associated with estimated glomerular filtration rate (r = −0.46, p<0.001) and positively associated with interstitial inflammation (r = 0.309, p = 0.002) and interstitial fibrosis (r = 0.287, p = 0.004). Serum connective tissue growth factor level was a risk factor for doubling of serum creatinine in lupus nephritis ( p<0.001, hazard ratio = 1.015, 95% confidence intervals 1.008–1.022) in univariate analysis. Conclusions: Serum connective tissue growth factor levels were significantly higher in lupus and correlated with chronic renal interstitial injury and doubling of serum creatinine in patients with lupus nephritis.

Transforming Growth Factor-Beta 1(tgfβ1)and Its Clinical Significances in Patients with Nephritic Syndrome

Correlative Analysis Between Renal TGF-β1 Expression and Cell Apoptosis in a Rat Model of Cyclosporine-Induced Chronic Nephrotoxicity, and Effect of Tea Polyphenols on TGF-β1 Expression and Apoptosis

Urinary Serum- and Glucocorticoid-Inducible Kinase SGK1 Reflects Renal Injury in Patients with Immunoglobulin A Nephropathy

The clinical significance of the transforming growth factor-β receptor I expression in na?ve CD4 + T cells from patients with systemic lupus erythematosus

Clinical Significance of Serum Level of Transforming Growth Factor-Beta 1 in Patients with Chronic Idiopathic Thrombocytopenic Purpura

[Expression of Transforming Growth Factor-Beta1 in Renal Fibrosis of Human Mesengial Proliferative Glomerulonephritis].

Urinary TGF-1 Has a Supplementary Value in Predicting Renal Function Recovery Post Unilateral Ureteral Obstruction.

Changes of Renal Tissue TNF-α,Plasma TNF-α and Urine TNF-α in Patients with Primary Nephrotic Syndrome

[Correlation Between Urinary Biomarkers and Pathological Lesions in Drug-Induced Tubulointerstitial Nephritis].

Evaluation of TGF-β1 and MCP-1 Expression and Tubulointerstitial Fibrosis in Children with Henoch-Schönlein Purpura Nephritis and IgA Nephropathy: A Clinical Correlation.

Serum Levels of Transforming Growth Factor Beta 1 in Systemic Lupus Erythematosus Patients

Monocyte Chemotactic Protein-1, Fractalkine, and Receptor for Advanced Glycation End Products in Different Pathological Types of Lupus Nephritis and Their Value in Different Treatment Prognoses.

The Serum Levels of Connective Tissue Growth Factor in Patients with Systemic Lupus Erythematosus and Lupus Nephritis

Serum tumour necrosis factor-alpha as a marker of disease activity in children with nephrotic syndrome

Study of the Urinary TGF-β1 Profile in Diabetic Nephropathy: A Single-Center Experience From India

[Significance of Urinary Biomarkers in Differential Diagnosis of Acute Tubulointerstitial Nephritis].

[The Expressions of TGF-beta1 and Smad 2 Mrna on Diseased Glomeruli and Their Significance in the Development of Glomerulosclerosis].

Change of the Nuclear Protein Level of GR, AP-1 and NF-κB During the Glucocorticoid Treatment in Idiopathic Nephrotic Syndrome

Clinical Significance of Urinary Biomarkers in Patients with Primary Focal Segmental Glomerulosclerosis.

Clinical Significance of Serum and Bone Marrow Levels of TGF-β 1 in Patients with Acute Leukemia

Expression of Response Gene to Complement-32 in Renal Tissue of Children with Immunoglobulin A Nephropathy